Detalhe da pesquisa
1.
Phase Ia dose escalation study of OBP-801, a cyclic depsipeptide class I histone deacetylase inhibitor, in patients with advanced solid tumors.
Invest New Drugs
; 40(2): 300-307, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34613570
2.
A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma.
Br J Cancer
; 124(4): 744-753, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33311588
3.
First-In-Human, First-In-Class, Phase I Trial of the Fucosylation Inhibitor SGN-2FF in Patients with Advanced Solid Tumors.
Oncologist
; 26(11): 925-e1918, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34288257
4.
First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumors.
Int J Cancer
; 145(7): 1798-1808, 2019 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30680712
5.
Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer.
Invest New Drugs
; 37(2): 315-322, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30191522
6.
Correction to: Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer.
Invest New Drugs
; 36(6): 1158, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30334109
7.
A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors.
Invest New Drugs
; 34(5): 604-13, 2016 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27424159
8.
New options for the adjuvant treatment of cutaneous melanoma?
Curr Oncol Rep
; 16(11): 409, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25286906
9.
A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas.
J Clin Oncol
; 41(9): 1714-1724, 2023 03 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36669146
10.
A First-in-Human Phase 1 Study of a Novel Selective Androgen Receptor Modulator (SARM), RAD140, in ER+/HER2- Metastatic Breast Cancer.
Clin Breast Cancer
; 22(1): 67-77, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34565686
11.
Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors.
J Immunother Cancer
; 10(8)2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35940825
12.
Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer.
J Hematol Oncol
; 14(1): 127, 2021 08 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-34407844
13.
Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer.
J Clin Oncol
; 39(12): 1360-1370, 2021 04 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-33513026
14.
Identifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial.
PLoS One
; 16(4): e0248097, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33826614
15.
Intratumoral DNA electroporation induces anti-tumor immunity and tumor regression.
Cancer Immunol Immunother
; 59(3): 409-17, 2010 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-19730859
16.
Expression of estrogenicity genes in a lineage cell culture model of human breast cancer progression.
Breast Cancer Res Treat
; 120(1): 35-45, 2010 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-19308726
17.
Molecular profiling of melanoma brain metastases compared to primary cutaneous melanoma and to extracranial metastases.
Oncotarget
; 11(33): 3118-3128, 2020 Aug 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-32913556
18.
Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR+, HER2- Advanced Breast Cancer.
Clin Cancer Res
; 26(24): 6417-6428, 2020 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32998962
19.
Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer.
Cancer Discov
; 10(1): 40-53, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31732494
20.
Her-2 DNA versus cell vaccine: immunogenicity and anti-tumor activity.
Cancer Immunol Immunother
; 58(5): 759-67, 2009 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-18836716